NW-1689
NW-1689 is a process-related impurity of safinamide mesilate (SAFM) . SAFM is a drug used to treat Parkinson's disease (PD) . It is a highly selective and reversible inhibitor of monoamine oxidase-B (MAO-B) and also blocks sodium channels and N-type calcium channels. These effects of SAFM help reduce the breakdown of dopamine and inhibit the release of glutamate. NW-1689 has a similar chemical structure to SAFM and has some similar pharmacological effects as SAFM, and can be used in Parkinson's disease research[1].
Product Specifications
CAS Number
405-85-6
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
Drug Derivative
Type
Reference compound
Related Pathways
Others
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/nw-1689.html
Smiles
C1=CC(=CC(=C1)F)COC2=CC=C(C=C2)C(=O)O
Molecular Formula
C14H11FO3
Molecular Weight
246.23
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P405-P501
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
E-Cadherin / CD324 (Intercellular Junction Marker) (4A2), CF740 conjugate, 0.1mg/mL
CD44 Standard (DF1485), CF405M conjugate, 0.1mg/mL
Cytokeratin 17 (E3), CF568 conjugate, 0.1mg/mL
CD10 (Membrane Metalloendopeptidase) (MME/1620), CF488A conjugate, 0.1mg/mL
